Channels - TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer :: FRELIP Discovery

Similar Items: TNFRSF17 as a complementary biomarker to PD-L1 for predicting the response to immunotherapy in urothelial bladder cancer

Quick Look
Emerging Predictive Biomarkers of Immunotherapy Sensitivity in Patients with Non-Small Cell Lung Cancer
Quick Look
Multi-Omics Analysis Reveals m7G Methylation-Related Genes May Be Involved in TGF-β Signaling-Mediated Anti-PD-L1 Response in Bladder Cancer
Quick Look
Overexpression of human epidermal growth factor receptor 2 protein in urothelial carcinoma of the urinary bladder in Ibadan: a single-institutional experience
Quick Look
The Role of PD-L1 in Lung Cancer: From Biology to Clinical Application
Quick Look
Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
Quick Look
Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER
Quick Look
Immune escape mechanisms revealed by multifunctional nanoprobes targeting PD‐L1 in hepatic cancer progression
Quick Look
Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer
Quick Look
A Novel Strategy for Treating Elderly Patients with Advanced Non-Small Cell Lung Cancer: Exploring the Efficacy and Safety of Anlotinib Combined with PD-1/PD-L1 Inhibitors
Quick Look
Machine learning and network pharmacology identify keloid biomarkers (AMPH, TNFRSF9) and therapeutic targets (IL6, HAS2) for aloe-derived quercetin
Quick Look
HMGB1 as Double-Edged Regulator of Cancer Therapy: Mechanistic Roles in Chemotherapy Resistance and Immunotherapy Response
Quick Look
Calcium-related genes predict prognosis, immune characteristics, and response to immunotherapy in LUAD patients
Quick Look
Annotation-free prediction of immunotherapy response in melanoma using single-cell transcriptomic data
Quick Look
Rationale and Design of the Cancer Immunotherapy Evidence Living (CIEL) Library: A Continuously Updated Clinical Trial Database of Cancer Immunotherapies
Quick Look
Dendritic Cell‐T Cell Crosstalk Mediated Cancer Immunotherapy
Quick Look
Analysis of Somatic Mutations and Immunotherapy Biomarkers in Chinese Patients With Non‐Small Cell Lung Cancer During 2019–2024: A Retrospective Study
Quick Look
Comprehensive spatial and immune profiling of metastatic mismatch repair–deficient colorectal cancer reveals response to immunotherapy
Quick Look
Comprehensive analysis and functional validation of key genes in bladder cancer progression
Quick Look
Phantom bladder pain
Quick Look
SUSCEPTIBILITY AND DIAGNOSTIC PROTEOMIC BIOMARKERS FOR URINARY SCHISTOSOMIASIS AND ASSOCIATED BLADDER PATHOLOGIES AMONG ADULTS IN EGGUA, OGUN STATE, NIGERIA
Quick Look
Co‐Designing Lung Cancer Rehabilitation Services for People Treated With Immunotherapy
Quick Look
A Versatile Polymer‐Based In Situ Nanovaccine to Boost Cancer Immunotherapy
Quick Look
A SUMOylation/immune-related gene signature predicts the prognosis and immunotherapy efficacy of patients with triple-negative breast cancer
Quick Look
Multilayered analysis of cisplatin resistance mechanisms in bladder cancer: from the cell membrane to organelles